U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C10H14O4
Molecular Weight 198.2158
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GUAIFENESIN

SMILES

COC1=C(OCC(O)CO)C=CC=C1

InChI

InChIKey=HSRJKNPTNIJEKV-UHFFFAOYSA-N
InChI=1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3

HIDE SMILES / InChI
Molecular Formula C10H14O4
Molecular Weight 198.2158
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the cough reflex and facilitate removal of the secretions. Guaifenesin is over-the-counter drug for the treatment of cough and common cold.

Approval Year

1961
146
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
MUCINEX

Approved Use

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive

Launch Date

2002
Palliative
Approved
8583
MUCINEX

Approved Use

Uses helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive

Launch Date

2002
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.7 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205474s005lbl.pdf
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GUAIFENESIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.2 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205474s005lbl.pdf
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GUAIFENESIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205474s005lbl.pdf
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GUAIFENESIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Other AEs: Headache, Sore throat...
Other AEs:
Headache
Sore throat
Indigestion
Nose bleed
Eye infection
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Other AEs: Headache, Sore throat...
Other AEs:
Headache
Sore throat
Indigestion
Nose bleed
Eye infection
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30946892
unhealthy, 63.7 years
Health Status: unhealthy
Age Group: 63.7 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/30946892
Disc. AE: Vomiting, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Vomiting (1 patient)
Diarrhea (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30946892
AEs

AEs

AESignificanceDosePopulation
Eye infection
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Headache
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Indigestion
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Nose bleed
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Sore throat
400 mg 6 times / day steady, oral
Highest studied dose
Dose: 400 mg, 6 times / day
Route: oral
Route: steady
Dose: 400 mg, 6 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Eye infection
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Headache
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Indigestion
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Nose bleed
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Sore throat
1200 mg 2 times / day steady, oral
Highest studied dose|Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: steady
Dose: 1200 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
healthy, 31. 3 years (range: 19–50 years)
Health Status: healthy
Age Group: 31. 3 years (range: 19–50 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/27121557
Diarrhea 1 patient
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30946892
unhealthy, 63.7 years
Health Status: unhealthy
Age Group: 63.7 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/30946892
Vomiting 1 patient
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30946892
unhealthy, 63.7 years
Health Status: unhealthy
Age Group: 63.7 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/30946892
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP 450
20
CYP 450
32
CYP 450
12
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP 450
22
 no
CYP 450
22
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP 450
32
 no
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY457034
https://www.001chemical.com/chem/93-14-1
3B Scientific (Wuhan) Corp
3B1-00290
http://www.3bsc.com/index/pro_info.php?id=20502
AA Blocks
AA006I85
https://www.aablocks.com/goods/Goods/detail?id=AA006I85
Aaron Chemicals
AR006IZX
http://www.aaronchem.com/93-14-1
abcr GmbH
AB117741
http://www.abcr.com/shop/en/AB117741
AbMole Bioscience
M5684
http://www.abmole.com/products/guaifenesin.html
Acadechem
ACDS-027519
http://www.acadechemical.com/product/102218
Aceschem
ACS024391
https://www.aceschem.com/catalog/93-14-1.html
Achemtek
0104-009846
http://www.achemtek.com/93-14-1
Acorn PharmaTech
ACN-046918
http://www.acornpharmatech.com/
AK Scientific, Inc. (AKSCI)
J10304
http://www.aksci.com/item_detail.php?cat=J10304
AK Scientific, Inc. (AKSCI)
K695
http://www.aksci.com/item_detail.php?cat=K695
Alfa Aesar
A16827
https://www.alfa.com/en/catalog/A16827/
Alfa Chemistry
ACM93141
https://www.alfa-chemistry.com/guaiacol-glyceryl-ether-cas-93-14-1-item-289155.htm
Alfa Chemistry
AP93141-A
https://reagents.alfa-chemistry.com/product/guaifenesin-cas-93-14-1-18687.html
Alfa Chemistry
AP93141-B
https://reagents.alfa-chemistry.com/product/guaifenesin-cas-93-14-1-18688.html
Alsachim
1185
http://www.alsachim.com/product-C3030-glo.bal-view.html
Angene
AGN-PC-07A1ZS
http://www.angenechemical.com/productshow/AGN-PC-07A1ZS.html
Anward
ANW-43892
http://www.anward.com/pro_result/10795
Ark Pharm
AK402920
http://www.arkpharminc.com/products/93-14-1.html
Avantor Inc
101095-104
https://us.vwr.com/store/product/7889434/guaifenesin
BioCrick
BCN2977
http://www.biocrick.com/Guaifenesin-BCN2977.html
BioSynth
W-100252
https://www.biosynth.com/en/products/chemical-intermediates/basic-intermediates/products/W-100252.html
BLD Pharm
BD35456
http://www.bldpharm.com/products/93-14-1.html
BOC Sciences
1173019-31-2
https://isotope.bocsci.com/product/guaifenesin-13c3-cas-1173019-31-2-344506.html
Capot Chemical
21966
http://www.capotchem.com/en/21966.htm
Capot Chemical
PubChem21966
http://www.capotchem.com/en/21966.htm
Chem Scene
CS-2251
http://www.chemscene.com/93-14-1.html
ChemFaces
CFN90974
http://www.chemfaces.com/natural/Guaifenesin-CFN90974.html
ChemMol
30107646
http://www.chemmol.com/chemmol/30107646.html
ChemMol
49417058
http://www.chemmol.com/chemmol/49417058.html
Chemspace
CSSB00011215080
https://chem-space.com/CSSB00011215080
Clearsynth
CS-O-01591
https://www.clearsynth.com/en/CSO01591.html
CSNpharm
CSN16504
https://www.csnpharm.com/products/guaifenesin.html
DC Chemicals
DCAPI1387
http://www.dcchemicals.com//product_show-Guaifenesin_Guaiphenesin_.html
Finetech
FT-0613565
http://www.finetechnology-ind.com/prod/detail/pub/93-14-1.html
Finetech
FT-0669064
http://www.finetechnology-ind.com/prod/detail/pub/1189924-85-3.html
Hairui
HR135746
http://www.hairuichem.com/en/product/93-14-1.html
iChemical
EBD30930
http://www.ichemical.com/products/93-14-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network
LN00223050
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00223050
LGC Standards
DRE-C14056900
https://www.lgcstandards.com/US/en/p/DRE-C14056900
LGC Standards
LGCFOR0354.00
https://www.lgcstandards.com/US/en/p/LGCFOR0354.00
LGC Standards
MM0354.00
https://www.lgcstandards.com/US/en/p/MM0354.00
mcule
MCULE-8909929116
https://mcule.com/MCULE-8909929116/
MedChem Express
HY-B0264
https://www.medchemexpress.com/Guaifenesin.html
Molcore
MC457034
https://www.molcore.com/product/93-14-1
Parchem
12117
http://www.parchem.com/chemical-supplier-distributor/Guaifenesin-002117.aspx
Parchem
17012
http://www.parchem.com/chemical-supplier-distributor/Guaifenesin-Dc-95--007012.aspx
Sigma-Aldrich
1301007_USP
https://www.sigmaaldrich.com/catalog/product/usp/1301007?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
G0700000_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/g0700000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
G5627_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/g5627?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
PHR1027_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/phr1027?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
Y0001956_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/y0001956?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech
S011862
http://www.sinfoobiotech.com/product/1015260
Smolecule
S529562
http://www.smolecule.com/products/s529562
Smolecule
S748676
https://www.smolecule.com/products/s748676
TCI (Tokyo Chemical Industry)
G0159
http://www.tcichemicals.com/eshop/en/us/commodity/G0159/index.html
THE BioTek
bt-270358
https://www.thebiotek.com/product/inhibitors/bt-270358
VladaChem
VL274716-100G
https://www.vladachem.com/product.php?products=93-14-1
Yuhao Chemical
HL1212
http://www.chemyuhao.com/93-14-1.html
PubMed

PubMed

TitleDatePubMed
Sensitive spectrophotometric method for quantitation of guaifenesin and dropropizine in their dosage forms.
2010
Spontaneous dissolution of a guaifenesin stone.
2005-08
Dextromethorphan-induced delirium and possible methadone interaction.
2005-03
Ephedrine- and guaifenesin-induced nephrolithiasis.
2004-12
Pseudoephedrine and guaifenesin urolithiasis: widening the differential diagnosis of radiolucent calculi on abdominal radiograph.
2004-09-08
Bilateral guaifenesin ureteral calculi.
2004-01
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001-11
Guaifenesin- and ephedrine-induced stones.
1999-11
Abuse of guaifenesin-containing medications generates an excess of a carboxylate salt of beta-(2-methoxyphenoxy)-lactic acid, a guaifenesin metabolite, and results in urolithiasis.
1999-07
Fulminant hepatic failure associated with clarithromycin.
1996-02
Affective disorder following use of phenylpropanolamine.
1990-03
Hypertension in bulls and steers anesthetized with guaifenesin-thiobarbiturate-halothane combination.
1986-07
Potentiating effects of chlorpromazine on the paralysis and toxicity induced by guaiacal glyceryl ether in rats.
1972-12
Patents

Patents

05495052
1
JP2002511777A
420
JPH05139996A
1

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Guaifenesin can also be given in syrup form.
1 tablet every 12 hours (adults and children 12 years of age and over).
Route of Administration: Oral
In Vitro Use Guide
Sputum or mucus simulants were analyzed untreated and after the addition of guaifenesin at 1:5 volume to volume ratio for a contact period of 60 s. The concentration of guaifenesin was 20 mg/mL.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:55:16 GMT 2025
Edited
by admin
on Mon Mar 31 17:55:16 GMT 2025
Record UNII
495W7451VQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GUAIFENESIN
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
HUSTOSIL
Preferred Name English
FLOWTUSS COMPONENT GUAIFENESIN
Brand Name English
GUAIFENESIN [USP-RS]
Common Name English
GUAIFENESIN [HSDB]
Common Name English
MUCINEX
Brand Name English
GUAIFENESIN [USP MONOGRAPH]
Common Name English
(±)-3-(O-METHOXYPHENOXY)-1,2-PROPANEDIOL
Common Name English
METHPHENOXYDIOL
Common Name English
MUCINEX D COMPONENT GUAIFENESIN
Common Name English
GUAIFENESIN [JAN]
Common Name English
Guaifenesin [WHO-DD]
Common Name English
GUAIFENESIN [GREEN BOOK]
Common Name English
GUAIFENESIN [MART.]
Common Name English
GUAIFENESIN [MI]
Common Name English
GUAIFENESIN [EP MONOGRAPH]
Common Name English
MUCINEX DM COMPONENT GUAIFENESIN
Common Name English
CVT-2534
Code English
OBREDON COMPONENT GUAIFENESIN
Brand Name English
GLYCERYL GUAIACOLATE
Systematic Name English
GUAIFENESIN [USAN]
Common Name English
NSC-62112
Code English
guaifenesin [INN]
Common Name English
1,2-PROPANEDIOL, 3-(2-METHOXYPHENOXY)- (±)-
Systematic Name English
GUAIFENESIN [ORANGE BOOK]
Common Name English
GUAIFENSIN
Common Name English
GUAIACOL GLYCERYL ETHER
Systematic Name English
GUAIPHENESIN
Common Name English
GUAIFENESIN [VANDF]
Common Name English
ROBITUSSIN
Brand Name English
Classification Tree Code System Code
WHO-VATC QR05CA03
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
NCI_THESAURUS C29767
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
CFR 21 CFR 522.1086
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
WHO-VATC QM03BX90
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
CFR 21 CFR 341.78
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
CFR 21 CFR 341.18
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
CFR 21 CFR 522.1085
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
WHO-ATC R05CA03
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
Code System Code Type Description
SMS_ID
100000090413
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
EPA CompTox
DTXSID5023114
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
LACTMED
Guaifenesin
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
CAS
93-14-1
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
ChEMBL
CHEMBL980
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
PUBCHEM
3516
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
RXCUI
5032
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY RxNorm
NCI_THESAURUS
C29081
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
WIKIPEDIA
GUAIFENESIN
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
DRUG BANK
DB00874
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
HSDB
3089
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
IUPHAR
7617
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
EVMPD
SUB07973MIG
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
MESH
D006140
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
MERCK INDEX
m5861
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY Merck Index
FDA UNII
495W7451VQ
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
INN
968
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
DRUG CENTRAL
1336
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
DAILYMED
495W7451VQ
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
RS_ITEM_NUM
1301007
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
NSC
62112
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
ECHA (EC/EINECS)
202-222-5
Created by admin on Mon Mar 31 17:55:16 GMT 2025 , Edited by admin on Mon Mar 31 17:55:16 GMT 2025
PRIMARY
Related Record Type Details
Structure of GUAITHYLLINE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of .BETA.-(2-METHOXYPHENOXY)LACTIC ACID
METABOLITE -> PARENT
Structure of RANOLAZINE
PARENT -> METABOLITE
Related Record Type Details
Structure of GUAIFENESIN .BETA.-ISOMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 1,3-BIS(2-METHOXYPHENOXY)-2-PROPANOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Guaiacol
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of METHOCARBAMOL
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 1,1'-OXYBIS(3-(2-METHOXYPHENOXY)PROPAN-2-OL)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of GUAIFENESIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966